Market Overview

BMO's Physician Survey Results Indicate Good Health Of Endologix

Related ELGX
Mid-Afternoon Market Update: Genworth Financial Rises On Earnings Beat; Cray Shares Slide
Piper Jaffray Rates Endologix Overweight, Thinks Nellix Aneurysm Treatment Is 'Highly Approvable'

BMO Capital upgraded Endologix, Inc. (NASDAQ: ELGX) to Outperform from Market Perform, increasing the price target to $16 from $11.50. The move was triggered by the early feedback from physicians concerning the integration of TRIV, the de-risking of the Nellix data set, and positive survey results.

The physician survey revealed the following results:

  • 1. Seventy-nine percent of physicians are happy with the integration process
  • 2.They anticipate increasing Nellix utilization to 20 percent of cases over the next 12 months from 5 percent currently,
  • 3. Forty-six percent expect that Nellix will replace other EVAR devices, 17 percent expect that it will replace only the Ovation and AFX cases (cannibalization), and 37 percent believe that Nellix will shift more cases to minimally invasive procedures from open surgery
  • 4. Thirty-eight percent expect Nellix to increase the number of procedures, 21 percent expect it to change patient follow-up, and 21 percent believe it will provide peace of mind.

The biggest concern for the analysts remain the fact that 83 percent are still looking for more long-term clinical data.

Shares traded recently at $13.63, up 3.6 percent.

Latest Ratings for ELGX

Sep 2016Leerink SwannInitiates Coverage onMarket Perform
Aug 2016OppenheimerMaintainsOutperform
Aug 2016RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for ELGX
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Upgrades Price Target Analyst Ratings


Related Articles (ELGX)

View Comments and Join the Discussion!